Introduction {#S0001}
============

Lung cancer is the most common cancer and the first leading cause of malignancy worldwide.[@CIT0001] In China, 781,000 new cases of lung cancer and 626,000 deaths were reported in 2014, accounting for 27.26% of all cancer-related deaths.[@CIT0002] In spite of advances made in the early detection and treatment, the five-year survival rate for lung cancer is only 16.1%.[@CIT0003] Non-small-cell lung cancer (NSCLC) is the major pathological subtype of lung cancer, accounting for 80--85% of all cases. Epidemiological studies have shown that the prognosis of patients with NSCLC is affected by many factors, including pathological type,[@CIT0004] clinical stage,[@CIT0005] gender,[@CIT0006] and age.[@CIT0007] Patients with the same clinical features and demographic characteristics often demonstrate extensive heterogeneity in treatment sensitivity, disease recurrence, and survival outcomes after receiving the same treatment.[@CIT0008],[@CIT0009] Therefore, it is necessary to identify new biomarkers to predict patients' prognosis to improve the efficacy of cancer treatment.

In recent years, with the introduction of expanded knowledge of stem cells into oncology research, and the successful isolation and identification of tumor stem cells in various tumor tissues and cancer cell lines, the theory of cancer stem cells has received increasing attention.[@CIT0010] Recent studies have found that cancer stem cells are resistant to chemoradiotherapy, and although traditional chemoradiotherapy can kill most tumor cells and reduce tumor volume, some cancer stem cells remain and become the source of tumor resistance, recurrence, and metastasis.[@CIT0011],[@CIT0012]

As one of the main signaling pathways of cancer stem cells, the NOTCH signaling pathway plays an important role in the maintenance of self-renewal, multidirectional differentiation, and apoptosis of various cancer stem cells and thus participates in the regulation of cancer stem cells.[@CIT0013] Deregulation or mutation of NOTCH receptors, ligands, and signaling regulators is implicated in the occurrence, development, and progression of several human solid tumors, for example, breast cancer,[@CIT0014] colon cancer,[@CIT0015] and liver cancer,[@CIT0016] as well as NSCLC.[@CIT0017] Previous reports have demonstrated that NOTCH signaling is activated aberrantly and plays a critical role in the initiation, progression, and metastasis of NSCLC.[@CIT0018]

These characteristics of cancer stem cells are closely related to their unique signaling mechanisms. Mutations, including SNPs, in some key genes in these signaling pathways cause disorder or overactivation of the entire signaling pathway, leading to tumor development. Our previous study identified several SNPs in the NOTCH signaling pathway associated with the susceptibility of NSCLC in patients of the Chinese population.[@CIT0019] In the present study, we further explored the prognostic roles of candidate SNPs of the NOTCH signaling pathway in NSCLC patients and analyzed the interaction between genes and epidemiologic factors. The goal of this research was to improve the prediction of the prognosis of NSCLC and provide a basis for the development of treatment measures.

Materials and methods {#S0002}
=====================

Study subjects {#S0002-S2001}
--------------

We recruited 987 patients with primary NSCLC diagnosed by pathological histology from three hospitals (First Affiliated Hospital of Fujian Medical University, Fujian Medical University Union Hospital, and Fuzhou General Hospital of Nanjing Military Command) between January 2006 and December 2012. All NSCLC patients were of the Chinese population. This study was conducted in accordance with the Declaration of Helsinki，and was approved by the Fujian Medical University Ethics Committee. Written informed consent was obtained from all subjects before their enrolment in the study.

Data and sample collections {#S0002-S2002}
---------------------------

We obtained demographic data by in-person interviews using a standardized questionnaire that included gender, age, phone number, smoking status, history of lung diseases, and family history of cancer. We collected clinical information through hospital medical records, including pathological diagnosis, clinical stage, metastasis, the presence or absence of pleural effusion at the time of diagnosis, treatment information, date of diagnosis, and date of discharge. We conducted a standard follow-up by trained investigators using medical records or telephone interviews. The latest follow-up data in this analysis were obtained by December 1, 2017.

Before treatment, we collected a 5 mL blood sample from each participant for genomic DNA extraction. The sample was taken in the laboratory using the Oragene DNA self-collection kit (DNA Genotek, OraSure Technologies, Inc., Ottawa, ON, Canada).

Selection and genotyping of SNPs {#S0002-S2003}
--------------------------------

On the basis of data in Genebank (<http://www.ncbi.nlm.nih.gov/Genebank>), dbSNP (<http://www.ncbi.nlm.nih.gov/SNP>), and the International HapMap database (<http://www.hapmap.org>), we selected SNPs with the minimum allele frequency (MAF) threshold of 0.10, r2\>0.8 to explore the association between SNPs in *NOTCH* signaling and the prognosis of NSCLC ([Table 1](#T0001){ref-type="table"}). We conducted SNP genotyping using matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF-MS) with the Sequenom platform according to the manufacturer's iPLEX Application Guide (Sequenom Inc, San Diego, CA, USA). We analyzed results using the MassArrayTyper 4.0 Software. After we processed all of the test samples, we selected 10% of the samples at random and reran the samples for quality control purposes. Genotyping call rates were greater than 90%.Table 1Information about selected SNPs in NOTCH signalingGeneSNPChromoome positionLocationMAF-CHBAllele Change*NOTCH3*rs381518819p13.12Exon30.451G→A*NOTCH4*rs9158946p21.32Exon30.478A→C*NOTCH4*rs5206926p21.32Exon50.098A→G*JAG1*rs870820p12.2Exon260.183A→G*DLL1*rs10335836q27Exon110.280A→C*HES2*rs113641p36.31Exon40.159G→A*HEY1*rs10464728q21.13Exon50.305C→A*HEY2*rs37346376q22.31Exon50.195A→C[^1]

Statistical methods {#S0002-S2004}
-------------------

We defined overall survival (OS) as the time from the date of diagnosis until the date of death from any cause or to the date of the last follow-up. We applied four genetic models (codominant, dominant, additive, and recessive) to assess the association between the SNPs and the clinical outcomes of the sample NSCLC patients. We considered the model with the smallest *P-*value to be the best-fitting model. We employed the Kaplan-Meier method to draw the overall survival curves of the SNPs and used the log-rank test to compare the differences between groups. We fitted univariate and multivariate analyses with Cox proportional hazard regressions to calculate crude or adjusted hazard ratios (HR*s*) and their 95% confidence intervals (CIs). We used the stepwise Cox regression model to determine independent predictive factors of the NSCLC prognosis. In addition, we analyzed the additive and multiplicative interactions between the SNPs and epidemiologic factors, for which we found heterogeneity in the stratification analysis. All statistical tests were two-sided, and statistical significance was set at *P*\<0.05. All statistical analyses were carried out by SPSS software version 22.0 (SPSS Inc., Chicago, IL, USA) and Stata software version 14.0 (Stata Corp, College Station, TX, USA).

Results {#S0003}
=======

Characteristics and survival status of NSCLC patients {#S0003-S2001}
-----------------------------------------------------

Demographic characteristics for the 987 NSCLC patients are provided in [Table 2](#T0002){ref-type="table"}. The median age at the time of NSCLC diagnosis was 59 years (range 23--86 years). Most patients were male (71.6%). The overall median survival time (MST) for the entire cohort of patients was 25.0 months. The associations between clinical pathology characteristics and outcomes in NSCLC patients are also summarized in [Table 2](#T0002){ref-type="table"}. The log-rank test showed that the MST varied significantly based on gender, smoking status, history of lung diseases, clinical stage, metastasis, and pleural effusion, as well as surgical treatment (log-rank *P*\<0.05). We used the Cox proportional hazards regression model to identify the prognostic factors of overall survival (OS). Univariate analysis showed that patients who accepted surgical treatment (HR =0.35, 95% CI =0.30--0.41) were associated with significantly better OS. Males (HR =1.39, 95% CI =1.18--1.64), smokers (HR =1.29, 95% CI =1.11--1.50), patients with a history of lung diseases (HR =1.33, 95% CI =1.15--1.55), patients at clinical stage III or IV (HR =2.72, 95% CI =2.33--3.18), patients with metastasis (HR =2.74, 95% CI =2.31--3.25), and patients with pleural effusion at the time of diagnosis (HR =1.56, 95% CI =1.34--1.82) showed significant association with poor OS. We did not find any association, however, between other tested clinical characteristics and outcomes. Therefore, further adjustment was made for gender, clinical stage, metastasis, pleural effusion, and surgery in the multivariate Cox regression to control for possible confounding of the main effects of the rs915894 in the prognosis of NSCLC.Table 2Distribution of characteristics in Chinese patients with non-small-cell lung cancer (n=987) and prognosis analysisVariablePatients (n=987) N (%)Deaths (n=749) N (%)MST (months)Log-rank *P*HR (95% CI)GenderFemale280 (28.4)190 (25.4)34.5**\<0.001**1.00Male707 (71.6)559 (74.6)23.1**1.39 (1.18--1.64)**Age (years)\<60492 (49.8)360 (48.1)26.50.0551.00≥60495 (50.2)389 (51.9)23.71.15 (1.00--1.33)SmokingNo371 (37.6)261 (34.8)29.9**0.001**1.00Yes616 (62.4)488 (65.2)23.0**1.29 (1.11--1.50)**History of lung diseasesNo651 (66.0)476 (63.6)27.6**\<0.001**1.00Yes336 (34.0)273 (36.4)22.3**1.33 (1.15--1.55)**Family history of cancerNo788 (79.8)601 (80.2)25.50.6951.00Yes199 (20.2)148 (19.8)22.81.04 (0.87--1.24)Pathological typesAdenocarcinoma579 (58.7)432 (57.7)26.70.3041.00Squamous cell carcinoma305 (30.9)241 (32.2)23.21.13 (0.97--1.32)Others103 (10.4)76 (10.1)21.81.08 (0.85--1.38)Clinical stageI+II413 (41.8)241 (32.2)60.3**\<0.001**1.00III+IV574 (58.2)508 (67.8)18.1**2.72 (2.33--3.18)**MetastasisNo327 (33.1)174 (23.2)75.2**\<0.001**1.00Yes660 (66.9)575 (76.8)19.9**2.74 (2.31--3.25)**Pleural effusionNo698 (70.7)502 (67.0)29.5**\<0.001**1.00Yes289 (29.3)247 (33.0)18.7**1.56 (1.34--1.82)**SurgeryNo444 (45.0)407 (54.3)16.6**\<0.001**1.00Yes543 (55.0)342 (45.7)46.5**0.35 (0.30**--**0.41)**ChemotherapyNo297 (30.1)219 (29.2)22.90.6991.00Yes690 (69.9)530 (70.8)26.10.97 (0.83--1.14)RadiotherapyNo802 (81.3)592 (79.0)24.30.6961.00Yes185 (18.7)157 (21.0)29.11.04 (0.87--1.24)[^2]

Association between genotypes and survival of NSCLC {#S0003-S2002}
---------------------------------------------------

From the univariate Cox regression analysis, we found that patients who carried the rs11364 AG variant genotype (general model: *P*=0.028, HR =1.21, 95% CI =1.02--1.43) and AG+AA variant genotype (dominant model: *P*=0.036, HR =1.19, 95% CI =1.01--1.40) had a significantly shorter MST compared with those with the GG genotype. We did not observe a significant effect for SNP rs11364 when the analysis was adjusted by gender, age, smoking, history of lung diseases, family history of cancer, pathological types, clinical stage, metastasis, pleural effusion, surgery, chemotherapy, and radiotherapy. In contrast, we did not find any association between rs915894 and the prognosis of NSCLC before adjustment ([Figure 1](#F0001){ref-type="fig"}). Adjusting possible confounding factors, we observed that compared with patients carrying the rs915894 homozygous AA genotype, those with the AC genotype (adjusted HR =0.83, 95% CI *=*0.70--0.99, adjusted *P*=0.039) and the AC+CC genotype (adjusted HR =0.83, 95% CI *=*0.71--0.98, adjusted *P*=0.030) had a significantly decreased risk of death from lung cancer ([Table 3](#T0003){ref-type="table"}).Table 3Association between SNPs in the NOTCH signal pathway and clinical outcomes in Chinese patients with NSCLCSNPGenotypeDeath/TotalMST (months)UnivariateMultivariateHR (95% CI)*P*-valueHR (95% CI)^a^*P*-value^a^rs3815188GG356/27722.931.000.5221.000.669AG358/26525.000.91 (0.77--1.08)0.2860.95 (0.80--1.13)0.569AA114/8923.201.00 (0.79--1.27)0.9920.90 (0.70--1.15)0.396Dominant472/35424.430.93 (0.80--1.09)0.3890.94 (0.80--1.10)0.436Recessive714/54224.371.05 (0.84--1.31)0.6810.92 (0.73--1.16)0.489Additive0.98 (0.87--1.09)0.6800.95 (0.85--1.06)0.370rs915894AA287/22324.271.000.7241.000.095AC428/32124.570.94 (0.79--1.11)0.468**0.83 (0.70--0.99)0.039**CC167/12522.170.93 (0.75--1.16)0.5210.84 (0.67--1.05)0.122Dominant595/44624.330.94 (0.80--1.10)0.424**0.83 (0.71--0.98)0.030**Recessive715/54424.430.97 (0.80--1.17)0.7320.94 (0.77--1.14)0.529Additive0.96 (0.86--1.07)0.4710.90 (0.81--1.01)0.075rs520692AA753/57224.031.000.2701.000.342AG180/13726.930.95 (0.78--1.14)0.5501.06 (0.88--1.28)0.542GG7/473.600.47 (0.17--1.24)0.1270.52 (0.19--1.39)0.191Dominant187/14128.070.92 (0.76--1.10)0.3631.03 (0.86--1.24)0.758Recessive933/70924.370.47 (0.18--1.26)0.1320.51 (0.19--1.38)0.183Additive0.90 (0.76--1.07)0.2251.00 (0.84--1.19)0.967rs8708AA638/49324.871.000.2271.000.307AG273/19725.370.90 (0.76--1.06)0.2000.92 (0.78--1.09)0.312GG38/3121.371.20 (0.83--1.72)0.3301.21 (0.84--1.75)0.310Dominant311/22824.430.93 (0.79--1.09)0.3610.95 (0.81--1.11)0.517Recessive911/69024.901.24 (0.86--1.77)0.2481.24 (0.86--1.79)0.245Additive0.97 (0.85--1.11)0.6930.99 (0.86--1.13)0.873rs1033583AA578/44724.331.000.6751.000.919AC296/21825.470.93 (0.79--1.10)0.3960.97 (0.82--1.14)0.696CC55/4328.800.94 (0.69--1.28)0.6941.01 (0.74--1.39)0.953Dominant351/26125.670.93 (0.80--1.09)0.3760.98 (0.84--1.14)0.743Recessive874/66524.430.96 (0.71--1.31)0.8031.02 (0.75--1.40)0.901Additive0.95 (0.84--1.08)0.4210.99 (0.87--1.12)0.830rs11364GG663/48725.401.000.0891.000.057AG236/19324.03**1.21 (1.02--1.43)0.028**1.16 (0.98--1.37)0.093AA29/2123.301.04 (0.67--1.61)0.8580.71 (0.46--1.11)0.136Dominant265/21423.77**1.19 (1.01--1.40)0.036**1.09 (0.93--1.29)0.286Recessive899/68024.870.99 (0.64--1.53)0.9650.68 (0.44--1.06)0.089Additive1.13 (0.99--1.30)0.0761.02 (0.89--1.17)0.800rs1046472CC622/48124.431.000.8291.000.362AC272/19724.330.95 (0.81--1.12)0.5601.05 (0.88--1.24)0.605AA47/3827.331.02 (0.73--1.42)0.9181.27 (0.91--1.78)0.162Dominant319/23524.370.96 (0.82--1.12)0.6261.08 (0.92--1.26)0.375Recessive894/67824.371.03 (0.75--1.43)0.8491.25 (0.90--1.75)0.183Additive0.98 (0.86--1.11)0.7471.09 (0.95--1.24)0.221rs3734637AA581/44525.531.000.2251.000.391AC311/23723.131.06 (0.91--1.24)0.4641.11 (0.95--1.31)0.185CC54/3732.430.78 (0.56--1.10)0.1550.98 (0.70--1.38)0.911Dominant365/27424.031.01 (0.87--1.18)0.8721.09 (0.94--1.28)0.247Recessive892/68224.770.77 (0.55--1.07)0.1180.94 (0.68--1.32)0.737Additive0.97 (0.86--1.09)0.6141.05 (0.93--1.19)0.418[^3] Figure 1Kaplan--Meier survival curves for NSCLC patients by the rs915894 in overall analysis in the dominant model.

The dominant model with the smallest *P-*value (*P*=0.003) was the best model for rs915894. Further multivariate Cox regression analysis showed that rs915894 was an independent predictive factor for NSCLC (AC/CC versus AA, HR =0.85, 95% CI =0.72--0.99, *P*=0.041). Other factors, including male gender (HR =1.23, 95% CI =1.03--1.47; *P*=0.020), clinical stage III or IV (HR =1.46, 95% CI =1.17--1.83, *P*=0.001), metastasis (HR =1.82, 95% CI =1.44--2.30, *P*\<0.001), and pleural effusion at the time of diagnosis (HR =1.25, 95% CI =1.06--1.47, *P*=0.009) were associated with shorter survival times, whereas receiving surgery (HR =0.49, 95% CI =0.41--0.58, *P*\<0.001) decreased the risk of death, as shown in [Table 4](#T0004){ref-type="table"}.Table 4COX regression analysis of the prognosis of non-small-cell lung cancer patientsVariables*β*SEHR95% CI*P*Gender0.2080.0891.23**1.03--1.470.020**Clinical stage0.3810.1141.46**1.17--1.830.001**Metastasis0.5980.1191.82**1.44--2.30\<0.001**Pleural effusion0.2190.0841.25**1.06--1.470.009**Surgery−0.7110.0880.49**0.41--0.58\<0.001**Radiotherapy−0.1620.0960.850.71--1.030.090rs915894−0.1690.0820.85**0.72--0.990.041**[^4]

Associations between rs915894 and the prognosis of NSCLC stratified by patient characteristics {#S0003-S2003}
----------------------------------------------------------------------------------------------

We conducted stratified analyses to evaluate the associations between genotype of rs915894 and the OS of NSCLC patients by gender, age, smoking, history of lung diseases, family history of cancer, pathological types, clinical stage, metastasis, pleural effusion, surgery, chemotherapy and radiotherapy. The significant protective effects conferred by rs915894 were more prominent in some subgroups with an HR ranging from 0.49 to 0.80 ([Figure 2](#F0002){ref-type="fig"}). As shown in [Figure 2](#F0002){ref-type="fig"}, we observed a significantly decreased risk of death associated with rs915894 AC/CC genotype in patients who were female (HR =0.71, 95% CI =0.51--0.99), were of less than 60 years old (HR =0.74, 95% CI =0.59--0.94), were not smokers (HR =0.63, 95% CI =0.48--0.84), had a history of lung diseases (HR =0.58, 95% CI =0.44--0.77), had a family history of cancer (HR =0.49, 95% CI =0.34--0.73), were without pleural effusion at time of diagnosis (HR =0.80, 95% CI =0.65--0.98), were without surgery (HR =0.77, 95% CI *=*0.62--0.96), or were accepting chemotherapy (HR =0.78, 95% CI =0.64--0.95).Figure 2Stratified analysis of the association between SNPs and the prognosis of NSCLC in the Chinese population. ^a^Adjusted by gender, age, smoking, history of lung diseases, family history of cancer, pathological types, clinical stage, metastasis, pleural effusion, surgery, chemotherapy, and radiotherapy.

The heterogeneity test found that the protective effect of the rs915894 AC/CC genotype on the prognosis of NSCLC was more pronounced in smokers, patients with a history of lung disease, and patients with a family history of cancer ([Figure 2](#F0002){ref-type="fig"}).

Joint effect between rs915894 and smoking, history of lung diseases, and family history of cancer on OS {#S0003-S2004}
-------------------------------------------------------------------------------------------------------

Prompted by these findings, we carried out an interaction analysis for the following combinations of factors: gene and smoking, gene and history of lung diseases, and gene and family history of cancer. We observed statistically significant multiplicative interactions. As presented in [Table 5](#T0005){ref-type="table"}, there were significant interactions between the genotype rs915894 and smoking, history of lung diseases, and family history of cancer (all *P*~interaction~ \<0.001). Compared with nonsmokers who carried AC+CC genotypes, patients with the AAgenotype who were not smokers had a significantly increased death risk (HR =1.62, 95% CI =1.24--2.13). We found similar results in patients carrying the AA genotype who also had a history of lung diseases (HR =1.52, 95% CI =1.18--1.96) and in patients carrying the AA genotype who had a family history of cancer (HR =1.77, 95% CI =1.29--2.42) as compared with the corresponding reference groups ([Table 5](#T0005){ref-type="table"}).Table 5Joint effect on OS of rs915894 genotypes and smoking, history of lung diseases, and family history of cancerGenotypeDeath/TotalHR (95% CI)HR (95% CI)^a^*P*-value^a^rs915894SmokingAC+CCNo139/2111.001.00AC+CCYes307/384**1.46 (1.19--1.78)**1.11 (0.83--1.47)0.494AANo89/114**1.41 (1.08--1.84)1.62 (1.24--2.13)\<0.001**AAYes134/173**1.34 (1.05--1.69)**1.12 (0.83--1.53)0.458*P* interaction**0.007**rs915894History of lung diseasesAC+CCNo285/3851.001.00AC+CCYes161/2101.11 (0.92--1.35)0.91 (0.74--1.11)0.326AANo141/194**0.93 (0.76--1.14)**1.00 (0.82--1.23)0.980AAYes82/93**1.66 (1.30--2.12)1.52 (1.18--1.96)0.001***P* interaction**0.003**rs915894Family history of cancerAC+CCNo356/4671.001.00AC+CCYes90/1280.88 (0.70--1.10)0.84 (0.67--1.07)0.157AANo178/2350.96 (0.80--1.15)1.06 (0.88--1.27)0.543AAYes45/52**1.53 (1.12--2.09)1.77 (1.29--2.42)\<0.001***P* interaction**0.001**[^5]

Discussion {#S0004}
==========

In this study, we investigated the association of genetic polymorphisms in the genes of the NOTCH signaling pathway with the prognosis of NSCLC patients. We demonstrated that a variant genotype (AC+CC) of rs915894 in the *NOTCH4* gene was significantly associated with a better prognosis of NSCLC when compared with AA genotypes, whereas we did not observe a significant association between other SNPs selected and the clinical outcomes of NSCLC patients. Moreover, multivariate COX regression analysis showed that rs915894 affected the prognosis of NSCLC patients. The favorable prognostic effect of rs915894 was more evident in specific subgroups of NSCLC patients. Additionally, the joint analysis found a significant interaction between genes and epidemiological elements. To the best of our knowledge, this study is the first to report the association between *NOTCH4* gene polymorphisms and NSCLC prognosis. Once validated, *NOTCH4* SNP rs915894 may be used as a prognostic marker in combination with epidemiological factors to make decisions about individualized treatment of NSCLC.

In the stratified analysis, with respect to SNP rs915894, we observed that more significant HR was shown for patients in the nonsmoking subgroup and for patients who had a history of lung diseases or a family history of cancer. These results indicated that SNP rs915894 might be a promising biomarker for specific subgroups, and thus it could contribute to individualized prediction in specific populations. In addition, joint analysis revealed strong effects from the combinations of rs915894 and smoking, rs915894 and history of lung diseases, and rs915894 and family history of cancer. Smoking, history of lung diseases, and family history of cancer were defined as influencing factors for the prognosis of NSCLC.[@CIT0020],[@CIT0021]

Although previous studies have not provided related reports about the interaction of the rs915894 polymorphism and epidemiological factors, data revealed by the additive and multiplicative analyses have indicated that it would be promising to study the association of the rs915894 SNP with these factors. Cigarette by-products, especially nicotine, are potent mutagens and can be a direct cause of mutations in oncogenes or tumor suppressor genes.[@CIT0022],[@CIT0023] Li et al.[@CIT0024] conducted in vitro and in vivo experiments to investigate the association of smoking and mutations in the NOTCH signaling pathway in NSCLC. They found a direct effect of smoking on the NOTCH signaling pathway that leads to the progression of lung cancer. In addition, they further discovered that smoking significantly changed the SNPs in the signaling pathway, and specific SNPs modulated the expression levels of downstream molecules significantly. Prior investigation[@CIT0025] indicated that aberrant NOTCH signaling contributed to the pathophysiology of diverse lung disorders, such as chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis. Moreover, a family history of cancer may provide a synergy with the NOTCH signaling pathway at the gene level, which in turn amplifies the effect on the prognosis of NSCLC. We must consider, however, that genetic variations among various populations and residents of different regions may have contributed to this paper's finding that only rs915894 was related to NSCLC. A multicenter prospective study with a larger sample is needed to verify whether correlations exist between other NOTCH pathway SNPs and NSCLC.

NOTCH4, a transmembrane receptor of the Notch signaling pathway, is involved in the regulation of blood vessel formation and the remodeling and maturation of vascular networks.[@CIT0026] Accumulating evidence has illustrated the specificity of NOTCH4 for different cancers and has suggested the potential for NOTCH4 to be used as a marker for the diagnosis and prognosis of cancers. Zhang et al.[@CIT0015] reported that NOTCH4 might be an independent marker of relapse and prognosis in colorectal cancer patients, because overexpression of NOTCH4 in colorectal cancer cell lines suppressed tumor cell proliferation, migration, and invasion, while it induced apoptosis. Consistent with colorectal cancer, previous results demonstrated that high expression of NOTCH4 in ovarian cancer is correlated with a better prognosis.[@CIT0027],[@CIT0028] On the contrary, *NOTCH4* is an oncogene of breast tumors, and patients with high NOTCH4 expression had significantly lower OS rates compared with the NOTCH4 low expression group in breast cancer, especially luminal breast cancer.[@CIT0028],[@CIT0029] Studies have shown that NOTCH inhibitors slow cell proliferation and trigger apoptosis in ER-positive breast cancer cells.[@CIT0030] Studies[@CIT0031],[@CIT0032] also have demonstrated that the overexpression of NOTCH4 should promote the process of invasion and metastasis and meant poor prognosis of NSCLC, although a few studies showed no association between them.[@CIT0017],[@CIT0018] Thus, further work is needed to determine the association between the expression of NOTCH4 and the prognosis of NSCLC.

Currently, only a handful of studies have focused on the association between *NOTCH4* polymorphisms and the prognosis of cancer, especially NSCLC. In previous studies, there was no exploration of the association between rs915894 and the overall survival of NSCLC, which we investigated for the first time in our study. Located in exon3, rs915894 of *NOTCH4* is a missense mutation. We speculated that rs915894 could influence NOTCH4 expression activity and transcription of downstream proteins, resulting in a different NSCLC prognosis. Unfortunately, we did not collect the corresponding lung cancer tissue. Therefore, further investigation is needed to elucidate whether the rs915894 SNP in an exon could affect the expression of *NOTCH4* and NSCLC prognosis.

In addition, our data showed the association between rs11364 and the prognosis of NSCLC, even though the *P-*value did not reach statistical significance after adjustment. This result could be a function of the location of rs11364 in exon4 of *HES2*, the expression of which is closely related to the occurrence and development of cancer.[@CIT0033] Further study is needed to understand the effects of the rs11364 polymorphism on tumor progression.

In summary, our research discovered the important prognostic and predictive value of rs915894 in the *NOTCH4* gene, which may be regarded as a promising prognosis biomarker of NSCLC in the Chinese population. To the best of our knowledge, this study was the first to examine the association of *NOTCH4* polymorphisms with the overall survival of NSCLC patients. Nevertheless, some limitations of this study should be acknowledged. First, our sample size, although adequate for overall analysis, may be limited in some strata in the stratified analysis. This constraint might decrease the ability to detect the statistical associations between genotypes and strata. Second, all the subjects were recruited from Fujian Province, primarily from the city of Fuzhou, which could introduce selection bias. Third, because the lung tissue specimens were not collected in the previous study, gene expression analysis could not be performed, which failed to explore the mechanism of the effect of rs915894 on the prognosis of NSCLC. Future studies should include larger populations and other races to allow for a wider evaluation of the significance of the SNPs for NSCLC patients. Additional functional assays are warranted to reveal the underlying mechanisms implied in our findings.
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[^1]: **Abbreviations:** SNP, single-nucleotide polymorphism; MAF, minor allele frequency; JAG, Jagged; DLL, Delta-like; HES, hairy and enhancer of split; HEY, hairy/enhancer of split related with YRPW motif family members.

[^2]: **Note:** Bold values indicate significance.

[^3]: **Notes:** ^a^Adjusted by gender, age, smoking, history of lung diseases, family history of cancer, pathological types, clinical stage, metastasis, pleural effusion, surgery, chemotherapy, and radiotherapy. Bold values indicate significance.

[^4]: **Note:** Bold values indicate significance.

[^5]: **Note:** ^a^Adjusted by gender, age, smoking, history of lung diseases, family history of cancer, pathological types, clinical stage, metastasis, pleural effusion, surgery, chemotherapy, and radiotherapy. Bold values indicate significance.
